Dr. Reena Salgia, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Chicago, Pritzker School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 162
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Chicago, Pritzker School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
MI license 4301085791 -
Hepatology Physician
MI license 4301085791 -
Transplant Hepatology Physician
MI license 4301085791
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Henry Ford Health Hospital Detroit, MI
- Henry Ford Health West Bloomfield Hospital W Bloomfield, MI
- Henry Ford Allegiance Health Jackson, MI
- Wyandotte Hospital and Medical Center Wyandotte, MI
- Munson Healthcare Otsego Memorial Hospital Gaylord, MI
Medical groups
- Henry Ford Health System (2,570 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 162
- Services billed
- 363
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 65 | 51 |
| Established patient office or other outpatient visit, 30-39 minutes | 48 | 43 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 24 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ursodiol Other prescribers in Detroit, MI | 137 |
| Tacrolimus Other prescribers in Detroit, MI | 98 |
| Mycophenolate Mofetil Other prescribers in Detroit, MI | 96 |
| Xifaxan (rifaximin) Other prescribers in Detroit, MI | 88 |
| Spironolactone Other prescribers in Detroit, MI | 67 |
| Furosemide Other prescribers in Detroit, MI | 61 |
| Lenvima (lenvatinib mesylate) | 50 |
| Lactulose Other prescribers in Detroit, MI | 49 |
| Azathioprine Other prescribers in Detroit, MI | 48 |
| Prednisone Other prescribers in Detroit, MI | 43 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 7 payments worth $14,131 in total to this clinician.
| Gilead Sciences, Inc. | $7,393 |
|---|---|
| Cook Incorporated | $5,700 |
| AstraZeneca Pharmaceuticals LP | $940 |
| Cook Medical LLC | $98.00 |
| Compensation for services other than consulting (speaking, faculty) | $13,000 |
|---|---|
| Consulting Fee | $940 |
| Food and Beverage | $191 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Nov 14, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s description;4263005;AHM;11039142 | $4,930 |
| Cook Incorporated Nov 4, 2025 | Compensation for services other than consulting (speaking, faculty) ECHOTIP INSIGHT · Endoscopy | $2,850 |
| Cook Incorporated Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) ECHOTIP INSIGHT · Endoscopy | $2,850 |
| Gilead Sciences, Inc. Dec 10, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s description;4282255;AHM;11039142 | $2,370 |
| AstraZeneca Pharmaceuticals LP Nov 10, 2025 | Consulting Fee | $940 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 3 companies. The companies reported $65,077 in research payments for these studies, mostly to the institutions running them.
- Atezolizumab and bevacizumab tiragolumab in 1L unresectable hcc pts
Genentech, Inc. - A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
AbbVie Inc. · Active, not recruiting · NCT06109272 - A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib E7080,MK-7902 with Pembrolizumab MK-3475 in Combination with Transarterial Chemoem…
Merck Sharp & Dohme LLC - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc. - A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC
Genentech, Inc. - Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
AbbVie Inc. · Active, not recruiting · NCT05822752 - M24-147 - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma
AbbVie Inc. - Tecentriq plus Avastin Following Curative Resection in Patients at High Risk of Recurrence
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.